Heron Therapeutics Inc
Abierto
SectorSanidad
0.3 -3.23
Resumen
Variación precio
24h
Mínimo
0.3
Máximo
0.32
Ingresos | 2.6M -5.5M |
|---|---|
Ventas | 3M 38M |
BPA | -0.03 |
Margen de beneficios | -14.573 |
Empleados | 128 |
EBITDA | 2.1M -5.5M |
Próximas Ganancias | 3 nov 2026 |
|---|
Capitalización Mercado | -36M 61M |
|---|---|
Apertura anterior | 3.53 |
Cierre anterior | 0.3 |
Noticias sobre sentimiento de mercado
By Acuity
11%
89%
18 / 340 Clasificación en Healthcare
Heron Therapeutics Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Heron Therapeutics Inc previsión
Sentimiento
By Acuity
18 / 340 Clasificación en Sanidad
Noticias sobre sentimiento de mercado
Coyuntura alcista notoria
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por encima de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Heron Therapeutics Inc
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
